An open-label study of quetiapine for delirium
Maneeton, B.; Maneeton, N.; Srisurapanont, M.
Journal of the Medical Association of Thailand 90(10): 2158-2163
2007
ISSN/ISBN: 0125-2208 PMID: 18041437 Document Number: 2963
Objective: To evaluate the effects of quetiapine treatment in patients with delirium.Material and Method: All patients with delirium were assessed The diagnosis of delirium was confirmed by using the Confusion Assessment Method (CAM). Quetiapine at the dose between 25 and 100 mg/day was given for 7 days. The efficacy of quetiapine on delirium was evaluated by using the Delirium Rating Scale (DRS) and the Clinical Global Impression-Severity scale (CGI-S). The extrapyramidal side effects were assessed by using the Modified (9-item) Simpson-Angus Scale (MSAS).Results: Twenty-two patients had delirium. Seventeen (10 males and 7 females) subjects with a mean age (SD) of 55.6 (18.6) years were included in the present study. Means (SDs) close and duration (SD) of quetiapine treatment were 45.7 (28.7) mg1day and 6.5(2.0) days, respectively. The DRS and CGI-S scores of days 2-7 were significantly lower than those of day 0 (p <0.001)for all comparisons). Only two subjects were shown to have mild tremor.Conclusion: Quetiapine within the range of 25-100 mg/day improves delirious condition within 24 hours of treatment. It is well-tolerated and has a very low propensity to induce extrapyramidal side effects. Further randomized, placebo-controlled trials are warranted.
Document emailed within 1 workday
